Jan 10 (Reuters) - Palvella Therapeutics Inc :
* PALVELLA THERAPEUTICS ANNOUNCES PUBLICATION OF RESULTS FROM PHASE 2 CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS IN THE JOURNAL OF VASCULAR ANOMALIES
* PALVELLA THERAPEUTICS INC - PHASE 3 TRIAL OF QTORIN RAPAMYCIN FOR MICROCYSTIC LMS WITH DATA EXPECTED Q1 2026
* PALVELLA THERAPEUTICS INC - QTORIN RAPAMYCIN WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS
* PALVELLA THERAPEUTICS INC - 100% PARTICIPANTS SHOW IMPROVEMENT AFTER 12 WEEKS OF QTORIN RAPAMYCIN
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。